Valproic acidInduced parkinsonism in the elderly: A comprehensive review of the literature

American Journal Geriatric Pharmacotherapy

Volumn 9, Issue 6, 2011, Pages 405-412

  Mahmoud, Fade ^a   Tampi, Rajesh R ^b,c  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Masonicare   (United States)

Author keywords

elderly; parkinsonism; valproic acid

Indexed keywords

CARBAMAZEPINE; LEVODOPA; LITHIUM; PLACEBO; VALPROIC ACID; TRANQUILIZER;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MANIA; MINI MENTAL STATE EXAMINATION; NARANJO ADVERSE DRUG REACTION SCORE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SEIZURE; UNIFIED PARKINSON DISEASE RATING SCALE; AGE; AGED; ALGORITHM; CHEMICALLY INDUCED DISORDER; TIME;

AGE FACTORS; AGED; ALGORITHMS; ANTIMANIC AGENTS; HUMANS; PARKINSONIAN DISORDERS; TIME FACTORS; VALPROIC ACID;

EID: 83555161677     PISSN: 15435946     EISSN: 18767761     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2011.09.002     Document Type: Review

References (59)

1. J. Wadzinski, R. Franks, D. Roane, M. Bayard Valproate-associated hyperammonemic encephalopathy J Am Board Fam Med 20 2007 499 502 (Pubitemid 350096953)
2. V. Mittal, S. Muralee, R.R. Tampi Valproic acid-induced hyperammonemia in the elderly: a review of the literature Case Report Med 2009 2009 802121
3. C. Lennkh, C. Simhandl Current aspects of valproate in bipolar disorder Int Clin Psychopharmacol 15 2000 1 11 (Pubitemid 30058133)
4. D. Feil, K. Chuang, D.L. Sultzer Valproate-induced hyperammonemia as a cause of altered mental status Am J Geriatr Psychiatry 10 2002 476 478 (Pubitemid 34743352)
5. R. Aziz, B. Lorberg, R.R. Tampi Treatments for late-life bipolar disorder Am J Geriatr Pharmacother 4 2006 347 364 (Pubitemid 46211185)
6. S. Konovalov, S. Muralee, R.R. Tampi Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review Int Psychogeriatr 20 2008 293 308 (Pubitemid 351230232)
7. T.M. Gardner, R. Aziz, S. Muralee, R.R. Tampi Valproic acid-induced myoclonus in a demented patient: a case report Case Report Med 2009 2009 392091
8. V. Wils, G. Goluke-Willemse Extrapyramidal syndrome due to valproate administration as an adjunct to lithium in an elderly manic patient Int J Geriatr Psychiatry 12 1997 272 (Pubitemid 27182011)
9. C. Armon, C. Shin, P. Miller et al. Reversible parkinsonism and cognitive impairment with chronic valproate use Neurology 47 1996 626 635 (Pubitemid 26307288)
10. M. Onofrj, A. Thomas, C. Paci Reversible parkinsonism induced by prolonged treatment with valproate J Neurol 245 1998 794 796 (Pubitemid 28505274)
11. M.M. Hoehn, M.D. Yahr Parkinsonism: onset, progression and mortality Neurology 17 1967 427 442
12. M. Iijima Valproate-induced parkinsonism in a demented elderly patient J Clin Psychiatry 63 2002 75 (Pubitemid 34113491)
13. K. Easterford, P. Clough, M. Kellett et al. Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate Neurology 62 2004 1435 1437 (Pubitemid 38526068)
14. K. Masmoudi, V. Gras-Champel, H. Masson, M. Andrejak Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases Pharmacopsychiatry 39 2006 9 12 (Pubitemid 43235443)
15. A.J. Ristic, N. Vojvodic, S. Jankovic et al. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy Epilepsia 47 2006 2183 2185 (Pubitemid 44952275)
16. M.L. Gaubert, A. Cougnaud, A. Ghali et al. Loss of autonomy related to valproic acid intake J Am Geriatr Soc 54 2006 1971 (Pubitemid 44915867)
17. C. Zadikoff, R.P. Munhoz, A.N. Asante et al. Movement disorders in patients taking anticonvulsants J Neurol Neurosurg Psychiatry 78 2007 147 151 (Pubitemid 46220211)
18. G.J. Macphee, D.A. Stewart Diagnosis of parkinsonism in older patients receiving sodium valproate Mov Disord 22 2007 1211 (Pubitemid 47067244)
19. Z. Salazar, L. Tschopp, C. Calandra, F. Micheli Pisa syndrome and parkinsonism secondary to valproic acid in Huntington's disease Mov Disord 23 2008 2430 2431
20. M.J. Sleegers, J.J. Beutler, W.J. Hardon et al. Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus J Am Geriatr Soc 58 2010 799 801
21. R.P. Munhoz, L.C. Werneck, H.A. Teive The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics Clin Neurol Neurosurg 112 2010 431 435
22. C.L. Bowden, A.M. Brugger, A.C. Swann et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania The Depakote Mania Study Group JAMA 271 1994 918 924 (Pubitemid 24083217)
23. H.G. Pope Jr, S.L. McElroy, P.E. Keck Jr, J.I. Hudson Valproate in the treatment of acute mania A placebo-controlled study Arch Gen Psychiatry 48 1991 62 68
24. M.J. Alvarez-Gomez, J. Vaamonde, J. Narbona et al. Parkinsonian syndrome in childhood after sodium valproate administration Clin Neuropharmacol 16 1993 451 455 (Pubitemid 23292101)
25. O. Papazian, E. Canizales, I. Alfonso et al. Reversible dementia and apparent brain atrophy during valproate therapy Ann Neurol 38 1995 687 691
26. E. Sasso, S. Delsoldato, A. Negrotti, D. Mancia Reversible valproate-induced extrapyramidal disorders Epilepsia 35 1994 391 393 (Pubitemid 24138827)
27. B.S. Zaret, R.A. Cohen Reversible valproic acid-induced dementia: a case report Epilepsia 27 1986 234 240 (Pubitemid 16065365)
28. Y. Baba, J.D. Putzke, N.R. Whaley et al. Gender and the Parkinson's disease phenotype J Neurol 252 2005 1201 1205 (Pubitemid 41443619)
29. M.J. Farrer Genetics of Parkinson disease: paradigm shifts and future prospects Nat Rev Genet 7 2006 306 318
30. A. Barzilai, E. Melamed Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease Trends Mol Med 9 2003 126 132 (Pubitemid 36433894)
31. J.A. Obeso, M. Rodriguez-Oroz, C. Marin et al. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits Neurology 62 1 Suppl 1 2004 S17 S30
32. J.A. Obeso, M.C. Rodriguez-Oroz, J.L. Lanciego, M. Rodriguez Diaz How does Parkinson's disease begin? The role of compensatory mechanisms Trends Neurosci 27 2004 125 127 author reply 127128
33. J. Nutt, A. Williams, C. Plotkin et al. Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological, and biochemical observations Can J Neurol Sci 6 1979 337 343 (Pubitemid 10222328)
34. P.A. Price, J.D. Parkes, C.D. Marsden Sodium valproate in the treatment of levodopa-induced dyskinesia J Neurol Neurosurg Psychiatry 41 1978 702 706 (Pubitemid 8372362)
35. J.S. Lai, C. Zhao, J.J. Warsh, P.P. Li Cytoprotection by lithium and valproate varies between cell types and cellular stresses Eur J Pharmacol 539 2006 18 26 (Pubitemid 43783516)
36. R.S. Williams, L. Cheng, A.W. Mudge, A.J. Harwood A common mechanism of action for three mood-stabilizing drugs Nature 417 2002 292 295 (Pubitemid 34534711)
37. K.D. Beck, J. Valverde, T. Alexi et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain Nature 373 1995 339 341
38. M. Bahat-Stroomza, Y. Barhum, Y.S. Levy et al. Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease J Mol Neurosci 39 2009 199 210
39. D. Kirik, C. Winkler, A. Bjorklund Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration J Neurosci 21 2001 2889 2896 (Pubitemid 32298229)
40. C. Lavedan, S. Buchholtz, R.L. Nussbaum et al. A mutation in the human neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degeneration Neurosci Lett 322 2002 57 61 (Pubitemid 34215030)
41. H. Dou, K. Birusingh, J. Faraci et al. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis J Neurosci 23 2003 9162 9170 (Pubitemid 37243817)
42. Y. Hao, T. Creson, L. Zhang et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis J Neurosci 24 2004 6590 6599 (Pubitemid 38971708)
43. P. Laeng, R.L. Pitts, A.L. Lemire et al. The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells J Neurochem 91 2004 238 251 (Pubitemid 39314954)
44. J.E. Goldman, S.H. Yen, F.C. Chiu, N.S. Peress Lewy bodies of Parkinson's disease contain neurofilament antigens Science 221 1983 1082 1084 (Pubitemid 13041967)
45. Y. Qian, Y. Zheng, E. Tiffany-Castiglioni Valproate reversibly reduces neurite outgrowth by human SY5Y neuroblastoma cells Brain Res 1302 2009 21 33
46. J.L. Eriksen, S. Przedborski, L. Petrucelli Gene dosage and pathogenesis of Parkinson's disease Trends Mol Med 11 2005 91 96 (Pubitemid 40348985)
47. H.R. Morris Genetics of Parkinson's disease Ann Med 37 2005 86 96 (Pubitemid 40593280)
48. G.K. Tofaris, M.G. Spillantini Alpha-synuclein dysfunction in Lewy body diseases Mov Disord 20 Suppl 12 2005 S37 S44
49. S. Arawaka, M. Wada, S. Goto et al. The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease J Neurosci 26 2006 9227 9238 (Pubitemid 44359849)
50. Y. Leng, D.M. Chuang Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity J Neurosci 26 2006 7502 7512 (Pubitemid 44315219)
51. K.A. Conway, J.D. Harper, P.T. Lansbury Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease Nat Med 4 1998 1318 1320 (Pubitemid 28512115)
52. B. Monti, E. Polazzi, L. Batti et al. Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death J Neurochem 103 2007 518 530 (Pubitemid 47498025)
53. A. Abeliovich, Y. Schmitz, I. Farinas et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system Neuron 25 2000 239 252 (Pubitemid 30316525)
54. L. Rumbach, J.M. Warter, A. Rendon et al. Inhibition of oxidative phosphorylation in hepatic and cerebral mitochondria of sodium valproate-treated rats J Neurol Sci 61 1983 417 423 (Pubitemid 14234269)
55. P.B. Luis, J.P. Ruiter, C.C. Aires et al. Valproic acid metabolites inhibit dihydrolipoyl dehydrogenase activity leading to impaired 2-oxoglutarate-driven oxidative phosphorylation Biochim Biophys Acta 1767 2007 1126 1133 (Pubitemid 47313391)
56. C.C. Aires, G. Soveral, P.B. Luis et al. Pyruvate uptake is inhibited by valproic acid and metabolites in mitochondrial membranes FEBS Lett 582 2008 3359 3366
57. J.S. Rao, R.P. Bazinet, S.I. Rapoport, H.J. Lee Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kappaB DNA binding activity and COX-2 mRNA Bipolar Disord 9 2007 513 520 (Pubitemid 47202514)
58. R.F. Bachmann, Y. Wang, P. Yuan et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage Int J Neuropsychopharmacol 12 2009 805 822
59. M.J. Blok, B.J. van den Bosch, E. Jongen et al. The unfolding clinical spectrum of POLG mutations J Med Genet 46 2009 776 785